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Phyllodes tumor is an extremely rare tumor of the breast. It occurs in females in the third and fourth decades. The
difficulty in distinguishing between phyllodes tumors and benign fibroadenoma may lead to misdiagnosis. Lymph
node involvement is rarely described in phyllodes tumors; for this reason, sentinel node biopsy may be warranted.
We present a case of a 33-year-old woman affected by huge tumor of the right breast with ulceration in the skin
with a rapid tumor growth and with omolateral axillary metastasis.
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Malignant phyllodes tumor is a rare lesion of the breast
that can mimic breast benign mass on clinical diagnosis;
on the other hand, it is characterized by a typical rapid
growth. Clinicians and breast radiologists should pay
particular attention to these features, in order to avoid a
delayed diagnosis resulting in an aggressive surgical ap-
proach. In particular, breast radiologists could take into
consideration ultrasound abnormalities in breast nodules
and could accurately evaluate axillary lymph nodes in
case of a breast lesion with rapid tumor growth. Here
we present a case of a woman affected by a phyllodes
tumor, an uncommon oncologic disease.Introduction
Phyllodes tumors have an incidence of 1 per 100,000
women and account for only 0.5% of all breast neo-
plasms [1]. They have been variously classified, such as
‘cystosarcoma phyllodes’.
The phyllodes tumor is classified into benign, malig-
nant, and borderline tumor according to histopatho-
logical features [2,3]; its clinical course is frequently
unpredictable. The malignant phyllodes tumor is rare
with a lower incidence than the benign counterpart. The
tumor usually occurs in 35- to 55-year-old women [4,5].* Correspondence: stefano.meroni@ieo.it
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unless otherwise stated.The tumor appears clinically as a round, mobile, and
painless mass and there is no clinical features to distin-
guish benign or malignant phyllodes tumors from be-
nign lesions [6]. This is the case of small-sized phyllodes
tumors that could not be distinguished from fibroaden-
omas. There are no pathognomonic mammographic or
ultrasound features [7]. So, pseudo angiomatous stromal
hyperplasia (PASH), fibroadenoma, intraductal papil-
loma, or complex cyst are the main differential diag-
noses. Rare malignant tumors, including medullary or
mucinous carcinoma, may be considered as well. Even
though imaging plays a fundamental role as a first
diagnostic approach, final diagnosis is confirmed only
by histological examination and immunohistochemical
analysis.
Surgical resection remains the gold standard of treat-
ment, whereas radiation therapy and chemotherapy have
an undefined role.
The incidence of local recurrence, distant metastasis,
and cancer-related death are relatively lower than previ-
ously reported [8].
In this case report, we discuss a patient who developed
a rapidly expanding malignant phyllodes breast tumor
with a diameter of about 40 cm and with omolateral ax-
illary lymph node metastasis.Case report
We report a case of a 33-year-old female with no history
of familiar huge phyllodes breast tumor or breast and
ovarian cancer.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Testori et al. World Journal of Surgical Oncology  (2015) 13:81 Page 2 of 4The patient had a small lump in the right breast,
which appeared 4 years earlier during pregnancy and
misinterpreted as mastitis.
The lump grew up gradually. She did not feel any pain
or discomfort. In the recent months, the lump grew rap-
idly and breast skin appeared dark in color.
Physical examination revealed an enlarged right
breast completely subverted by the neoplastic mass. It
was 40 cm × 30 cm × 10 cm in size. Figure 1 shows
the thin skin of right breast and the engorgement of
right breast superficial vein. No axillary lymph node
was palpable. The examination of the left breast was
normal.
Ultrasonography showed a nodular blood flow in the
heterogeneous lesion. These tumors can present cystic
echoes, generally due to hemorrhage, necrosis, and mu-
coid degeneration.
In order to prevent bleeding or infections, we decided
not to perform any interventional procedures for a pre-
operative diagnosis, considering the heterogeneous ultra-
sonographic features.Figure 1 Malignant phyllodes tumor of the right breast with a
diameter of 40 cm in a 33-year-old patient. The visible vessels,
the thinned skin, and ulceration through the skin with exudate and
foul smell are characteristics for large phyllodes tumors.Due to the large size of the tumor and to the surgical
indication for a total mastectomy, we did not perform
mammography.
A preoperative positron emission tomography (PET/
CT) scan was performed and showed a massive area
of pathological accumulation of the tracer 18 F-FDG
(18 F-Fludeoxyglucose) in the right breast suspected
for cancer. The photopenic portion of the lesion could
be a necrotic process. Right axillary lymph nodes
showed a rapid volume increase and a pathologic ac-
cumulation of the tracer.
Skeletal and lung X-rays were normal. Biochemical
examination revealed no significant abnormalities.
The right breast and major pectoral muscle were
excised with omolateral axillary lymphadenectomy
(Figure 2). The resected specimen was a huge mass;
the tumor did not invade surrounding tissues.
The histopathological examination showed a tumor
with stromal hypercellularity and the presence of benign
glandular elements; the margins of the specimen were
free of disease.
HE staining and immunohistochemistry results were
as follows: mitotic rates of 12 mitosis/10 high power
fields (HPF), Desmin (−), Vimentin (+), Ck Pool (−),
Ki67 (25-30%), SMA (+), S100 (−), CD117 (−), CD34
(+/−). The final diagnosis was malignant phyllodes
tumor with metastasis in one out of nine lymph nodes.
Postoperative course was uneventful and the patient
was discharged on the third postoperative day. Adjuvant
chemotherapy (adriamicyn and ifosfamide) and adiuvant
radiotherapy were administrated. Treatment was well
tolerated and the patient was symptom-free at 18-
month follow-up. Clinical and ultrasound examination
were performed every 6 months. We recommendedFigure 2 Operative finding during radical mastectomy with
partial resection of major pectoral muscle.
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contralateral breast.
Discussion
The phyllodes tumor of the breast is a rare disease usu-
ally presents as a large lump. In few cases, it is bilateral
or multifocal [1,3,5,6,8]. It occurs mainly in middle-aged
women. As reported in literature, mean age ranges from
30 to 52 years. Phyllodes tumors of the breast are com-
monly classified as benign tumors and rarely as border-
line or malignant tumors [2,3,9-11].
The low incidence of phyllodes tumors could explain
why the percentage of malignant phyllodes tumors re-
ported in literature varies from 8% to 45% [12].
The difficulty in distinguishing between phyllodes tu-
mors and benign fibroadenoma may lead to misdiag-
nosis. In fact, there are no characteristic features that
clinically distinguish phyllodes tumors from other breast
tumors.
Surgical treatment is generally the treatment of choice
for phyllodes tumors, regardless of its histological sub-
type. Most studies recommend a more than 1- to 2-cm
excision margin [4,5,13-16] based on the evidence that
local recurrence occurs more frequently in patients with
narrow surgical margins less than 1 to 2 cm.
However, an excision with the required margins is
often impossible in huge phyllodes tumors due to the
narrow area of breast tissue surrounding the lump.
Lymph node involvement is rarely described in
phyllodes tumors [9-11]; so, routine axillary lymph
node dissection is often unnecessary [8]. The most
common path is the hematogenous spread, which oc-
curs mostly in the lungs, pleura, and bones, such as in
sarcoma [17].
Based on the available clinical data [8], little is known
about malignant breast phyllodes tumors with positive
axillary lymph node. Nodal metastases are rare in these
patients; for this reason, sentinel node biopsy may be
warranted. Formal axillary dissection could be unneces-
sary, but we think that the removal of low axillary lymph
nodes (as in our case) may be recommended, especially
in those patients with palpable lymphadenopathy or
huge breast mass [18].
In our case, the preoperative PET/CT scan showed a
suspicious lymph node in the right axilla. So, we think
that some malignant breast phyllodes tumors can spread;
sentinel lymph node biopsy may evaluate axillary in-
volvement in these patients. It is difficult to make a cor-
rect preoperative evaluation in such cases but, in our
opinion, the sentinel lymph node biopsy is a reasonable
option.
The prognosis for malignant breast phyllodes tumors
is poor and the role of various treatment modalities is
not clearly defined due to the rarity of disease [19].According to Ramakant et al. [9], large or giant phyl-
lodes tumors (>10 cm) have higher cancer rates (42.5%)
and recurrence rates (41%) compared with smaller tu-
mors (21% malignancy rate and 29% recurrence rates).
So, more aggressive treatments and adequate resection
margins are needed. Radiation therapy is recommended
in these selected cases, as in our case, and should be ad-
ministrated within 4 months from surgery [6,19,20].
Multimodality postoperative treatment, such as adjuvant
chemotherapy and radiotherapy, are recommended in
tumors at high risk for local recurrence and metastatic
spread, but their use in malignant phyllodes tumors is
yet controversial.
Radiotherapy has been used with good results for local
control of the disease [21] and it may be considered for
high risk phyllodes tumors, including those greater than
5 cm, with stromal overgrowth, with more than 10 mi-
toses per HPF or with positive margins [6,19].Conclusions
Breast phyllodes tumor is a rare tumor. The early age
of onset and the rapid growth make this report a spe-
cial case.
The diagnosis was confirmed by pathology and immu-
nohistochemistry. Surgical extended resection is the
treatment of choice; we performed total mastectomy
with adequate surgical margins and omolateral axillary
lymph node dissection.
Adjuvant radiotherapy and chemotherapy may be
administered in patients with high-grade tumors (as in
our case), positive surgical margins, or postoperative
recurrence, but their role is undefined.
In conclusion, we underline that phyllodes breast can-
cer may spread to distant organs and to axillary lymph
nodes. Ultrasound abnormalities in breast nodules and
breast lesions with atypical clinical and radiological pre-
sentations may be taken into particular consideration.Consent
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